Menu Search
Equities

ACADIA Pharmaceuticals Inc

0A4W:LSE

ACADIA Pharmaceuticals Inc

Actions
  • Price (USD)17.61
  • Today's Change0.00 / 0.00%
  • Shares traded1.12k
  • 1 Year change-19.87%
  • Beta--
Data delayed at least 20 minutes, as of Nov 08 2024 18:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

  • Revenue in USD (TTM)929.24m
  • Net income in USD128.51m
  • Incorporated1997
  • Employees620.00
  • Location
    ACADIA Pharmaceuticals Inc12830 El Camino Real, Suite 400SAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 558-2871
  • Fax+1 (858) 558-2872
  • Websitehttps://acadia.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.